Placenta Growth Factor - Pipeline Review, H2 2020
Placenta Growth Factor - Pipeline Review, H2 2020
SUMMARY
According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2020'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 27 molecules.
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.
The report 'Placenta Growth Factor - Pipeline Review, H2 2020' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 1, 5, 6, 6 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Metastatic Colorectal Cancer, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Choroidal Neovascularization, Corneal Neovascularization, Graves' Ophthalmopathy, Medulloblastoma, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion, Retinopathy Of Prematurity, Solid Tumor and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2020'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 27 molecules.
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.
The report 'Placenta Growth Factor - Pipeline Review, H2 2020' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 1, 5, 6, 6 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Metastatic Colorectal Cancer, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Choroidal Neovascularization, Corneal Neovascularization, Graves' Ophthalmopathy, Medulloblastoma, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion, Retinopathy Of Prematurity, Solid Tumor and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Appendix
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Alteogen Inc, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2020
Pipeline by Cinnagen Co, H2 2020
Pipeline by Clover Biopharmaceuticals, H2 2020
Pipeline by Coherus BioSciences Inc, H2 2020
Pipeline by Formycon AG, H2 2020
Pipeline by Gene Techno Science Co Ltd, H2 2020
Pipeline by GlycoNex Inc, H2 2020
Pipeline by Huons Global Co Ltd, H2 2020
Pipeline by i2 Pharmaceuticals Inc, H2 2020
Pipeline by Lupin Ltd, H2 2020
Pipeline by Luye Pharma Group Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Alteogen Inc, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2020
Pipeline by Cinnagen Co, H2 2020
Pipeline by Clover Biopharmaceuticals, H2 2020
Pipeline by Coherus BioSciences Inc, H2 2020
Pipeline by Formycon AG, H2 2020
Pipeline by Gene Techno Science Co Ltd, H2 2020
Pipeline by GlycoNex Inc, H2 2020
Pipeline by Huons Global Co Ltd, H2 2020
Pipeline by i2 Pharmaceuticals Inc, H2 2020
Pipeline by Lupin Ltd, H2 2020
Pipeline by Luye Pharma Group Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
